Recent Updates
Recently added Catalysts
KURA Positive Sentiment Score: 60/100

Kura Oncology to Report Third Quarter 2025 Financial Results

Tuesday, October 28, 2025 1 min read
Key Takeaway: Kura Oncology, Inc. has announced that it will report its third quarter financial results for 2025 on November 4, 2025, prior to the opening of U.S. financial markets. The company, focused on precision medicines for cancer treatment, will also host a conference call and webcast to discuss these results. This event highlights Kura's commitment to transparency and communication with its investors and the media.

Market Sentiment Analysis

POSITIVE FACTORS

  • Kura Oncology will report its financial results, indicating ongoing operations.
  • Management will provide a corporate update, signaling engagement with stakeholders.

Full Press Release Details

SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report third quarter 2025 financial results on Tuesday, November 4, 2025, before the U.S. financial markets open. Kura’s management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the financial results and provide a corporate update.
The live webcast and archived replay of the event may be accessed on the investor relations section of the Company’s website at www.kuraoncology.com.
Investors and media:
gmann@kuraoncology.com

Frequently Asked Questions

When will Kura Oncology report its Q3 2025 financial results?

Kura Oncology will report its Q3 2025 financial results on November 4, 2025.

What time is the Kura Oncology conference call on November 4?

The conference call is scheduled for 8:00 a.m. ET / 5:00 a.m. PT.

Where can I access the webcast for Kura's financial results?

The webcast can be accessed on Kura Oncology’s investor relations website.

Who can be contacted for media inquiries at Kura Oncology?

Media inquiries can be directed to gmann@kuraoncology.com.

Tags: KURA Viatris Investor Conferences Healthcare financial results Q3 2025 precision medicines cancer treatment
Last updated: Oct 28, 2025